EP Patent

EP4385502A1 — A pharmaceutical formulation comprising metformin, pioglitazone and a sglt-2 inhibitor

Assigned to Sanovel Ilac Sanayi ve Ticaret AS · Expires 2024-06-19 · 2y expired

What this patent protects

The present invention relates to the pharmaceutical formulation comprising metformin or salts thereof, pioglitazone or salts thereof and a SGLT-2 inhibitor.

USPTO Abstract

The present invention relates to the pharmaceutical formulation comprising metformin or salts thereof, pioglitazone or salts thereof and a SGLT-2 inhibitor.

Drugs covered by this patent

Patent Metadata

Patent number
EP4385502A1
Jurisdiction
EP
Classification
—
Expires
2024-06-19
Drug substance claim
No
Drug product claim
No
Assignee
Sanovel Ilac Sanayi ve Ticaret AS
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.